Chromium (N = 20) Placebo (N = 19) P-value changea
Variable Baseline Week 8 Baseline Week 8
HOMA – IRb (units) 0.96 (1.35) 1.25 (2.09) 0.64 (3.24) 0.64 (2.04) NSc
Glucose AUC 5.77 ± 0.11 6.07 ± 0.13 5.78 ± 0.07 5.87 ± 0.15 NS
Triglycerides (mmol/L) 1.68 ± 0.17 1.64 ± 0.17 1.65 ± 0.23 1.30 ± 0.21 NS
Total Cholesterol (mmol/L) 4.18 ± 0.20 4.21 ± 0.18 4.38 ± 0.21 4.04 ± 0.18 0.013
LDL Cholesterol (mmol/L) 2.41 ± 0.18 2.61 ± 0.28 2.43 ± 0.21 2.24 ± 0.20 NS
HDL Cholesterol (mmol/L) 1.01 ± 0.05 1.12 ± 0.06 1.20 ± 0.09 1.21 ± 0.09 0.043
CD4 Count 676 ± 78 762 ± 104 686 ± 60.67 674.5 ± 63.21 NS
CRP (mg/dL) 2.9 ± 0.3 5.5 ± 0.5 3.2 ± 0.2 3.1 ± 0.2 NS
Systolic BP (mm/Hg) 128 ± 2 130 ± 3 124.3 ± 3.29 124.3 ± 2.86 NS
Diastolic BP (mm/Hg) 77 ± 2 74 ± 3 77.3 ± 2.03 74 ± 1.94 NS
BMI (kg/m2) 28.2 ± 0.8 27.3 ± 0.7 26.8 ± 1.1 27.0 ± 0.83 NS
Limb Fat % 45.9 ± 1.8 45.6 ± 2.4 49.2 ± 1.81 48.5 ± 7.84 NS
Trunk Fat % 54.2 ± 1.8 52.7 ± 1.8 50.9 ± 1.81 50.7 ± 1.65 NS
afrom an independent t –test comparing the change in the chromium group and the change in the placebo group
bHOMA – IR is represented as the median (range), this variable only
cfrom a Mann Whitney U test for this variable only
Glucose AUC is the area under the curve of the glucose x time curve for 0-180min following oral ingestion of 75g of glucose; CRP is C-reactive protein; limb and trunk fat % are the proportion of fat present in limbs or trunk as a proportion of total body fat, expressed as a %. Data are expressed as mean ± SEM. NS is non-significant, i.e. P>0.05.
Table 2: Metabolic changes with chromium supplementation for 2 months compared to placebo.